Abstract Number: 0299 • ACR Convergence 2024
Real-World Tolerability of Nintedanib in Connective Tissue Disease-Associated Interstitial Lung Disease
Background/Purpose: Nintedanib is an antifibrotic medication used to treat interstitial lung disease (ILD), including connective tissue disease-associated ILD (CTD-ILD). Clinical trials that led to its…Abstract Number: 1114 • ACR Convergence 2024
Nintedanib in Autoimmune Disease-related Interstitial Lung Disease: Real-life Effectiveness, Safety and Tolerance in a Spanish Multicenter Study
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of autoimmune diseases (AD). In recent years, new strategies for the treatment of progressive pulmonary fibrosis…Abstract Number: 2059 • ACR Convergence 2024
The Rs35705950 Promoter Variant of Muc5b Is Associated with Usual Interstitial Pneumonia in Antisynthetase Syndrome
Background/Purpose: Rs35705950 variant in the MUC5B gene promoter is a critical genetic risk factor in idiopathic pulmonary fibrosis (IPF). It has been associated with usual…Abstract Number: 0281 • ACR Convergence 2023
Is There a Decreased Risk of Developing CF Arthropathy in CF Patients Undergoing Treatment That Targets the F508del Mutation?
Background/Purpose: Cystic fibrosis (CF) is characterized by mutations within the CFTR (cystic fibrosis transmembrane conductance regulator) gene that result in a defect of the chloride…Abstract Number: 1514 • ACR Convergence 2023
Phase I Study to Evaluate the Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for Interstitial Lung Disease in Patients with Connective Tissue Disorders
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of morbidity and mortality in connective tissue disorders (CTD) including rheumatoid arthritis, scleroderma and inflammatory myopathies.…Abstract Number: 1927 • ACR Convergence 2023
Manifestations, Management and Outcomes of Interstitial Lung Disease Associated with Anti-synthetase Syndrome: A Systematic Literature Review
Background/Purpose: Anti-synthetase syndrome (ASS) is a chronic autoimmune inflammatory condition, characterized by myositis, interstitial lung disease (ILD), arthritis, Raynaud's phenomenon and mechanic's hands. This systematic…Abstract Number: 0358 • ACR Convergence 2023
Baseline Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis Associated Lung Disease (SJIA-LD) Cohort
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) associated lung disease (SJIA-LD) is an emerging and life-threatening clinical problem with urgent unmet needs including prevalence, pathogenesis, disease…Abstract Number: 1522 • ACR Convergence 2023
Treatment of Pulmonary Arterial Hypertension in Patients with Connective Tissue Diseases: A Meta-analysis
Background/Purpose: Treatment options for pulmonary arterial hypertension (PAH) have expanded in the last two decades. However, evidence for the treatment of connective tissue disease-associated PAH…Abstract Number: 1940 • ACR Convergence 2023
A Single-center, Observational, Retrospective, Case Control Study of Rituximab for the Treatment of Interstitial Pneumonia Associated with Autoimmune Features
Background/Purpose: Patients with interstitial lung diseases (ILD) and clinical features of autoimmunity who do not satisfy the classification criteria for a specific autoimmune rheumatic disease…Abstract Number: 0409 • ACR Convergence 2023
Prevalence of Pulmonary Manifestations in Patients with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, and Peripheral Spondyloarthritis
Background/Purpose: Pulmonary impairment is a common, yet poorly understood, extraarticular manifestation in rheumatic diseases, which is often inadequately screened and managed. This can result in…Abstract Number: 1530 • ACR Convergence 2023
Outcomes in Patients with Systemic Sclerosis Following Lung Transplantation: An Italian Multicentre Experience
Background/Purpose: Lung transplantation (LT) is gaining ground in managing advanced ILD in SSc patients. However, concerns remain among surgeons due to SSc's complexity, multiorgan involvement…Abstract Number: 2010 • ACR Convergence 2023
B-FROST: Chronic OBstructive Pulmonary Disease and Vertebral FRacture of OSTeoporotic Origin: Results of a Real-life Cohort
Background/Purpose: Chronic obstructive pulmonary disease (COPD) is a chronic disease of the airways. It is mainly caused by smoking. Active smoking is a risk factor…Abstract Number: 0617 • ACR Convergence 2023
Pulmonary Rehabilitation in Connective Tissue Disease-Related Interstitial Lung Diseases
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of connective tissue disease (CTD)1. Pulmonary rehabilitation (PR) can be utilized to improve dyspnea and quality…Abstract Number: 1588 • ACR Convergence 2023
Monocyte-derived Macrophages Accumulate in the Lungs in anti-MDA5+ Dermatomyositis with RP-ILD: Proinflammatory and Profibrotic Phenotype Revealed by Single-cell RNA Sequencing
Background/Purpose: Anti-melanoma differentiation-associated gene 5-positive dermatomyositis (anti-MDA5+ DM) is a rare inflammatory autoimmune disease with impressively life-threatening rapid progressive interstitial lung disease (RP-ILD). The mechanism…Abstract Number: 2173 • ACR Convergence 2023
Window of Opportunity in the Treatment of Rheumatoid Arthritis-Interstitial Lung Disease with Abatacept. National Multicenter Study of 509 Patients
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated efficacy in the treatment of RA-ILD, especially if…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 14
- Next Page »